Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavisant - BenevolentAI/Johnson & Johnson

Drug Profile

Bavisant - BenevolentAI/Johnson & Johnson

Alternative Names: Bavisant; BEN-2001; JNJ-1074; JNJ-31001074

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Developer BenevolentAI; Johnson & Johnson
  • Class Morpholines; Neuropsychotherapeutics; Piperazines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 25 Jul 2022 Discontinued - Phase-I for Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (PO) Johnson & Johnson website, July 2022
  • 25 Jul 2022 Discontinued - Phase-II for Attention-deficit hyperactivity disorder in USA (PO) (Johnson & Johnson website, July 2022)
  • 25 Jul 2022 Discontinued - Phase-II for Narcolepsy in United Kingdom, Spain, USA, Germany, Czech Republic (PO) (Johnson & Johnson website, July 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top